Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

Erstveröffentlichung

2017

Authors

Einsele, Hermann

Engelhardt, Monika

Tapprich, Christoph

Mueller, Juergen

Liebisch, Peter

et al.

Wissenschaftlicher Artikel

Published in

British Journal of Haematology ; 179 (2017), 4. - S. 586-597. - ISSN 0007-1048. - eISSN 1365-2141

Link to publication

https://dx.doi.org/10.1111/bjh.14920

Institutions

UKU. Klinik für Innere Medizin III

Subject headings

[Free subject headings]: multiple myeloma | bortezomib | cyclophosphamide | dexamethasone | induction therapy | stem-cell transplantation | minimal residual disease | multiparameter flow-cytometry | induced peripheral neuropathy | newly-diagnosed patients | high-risk cytogenetics | high-dose therapy | plus dexamethasone | hovon-65/gmmg-hd4 trial | chromosomal-aberrations
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record